Abstract
Acute pancreatitis is an acute inflammatory process of the pancreas. Drugs are a relatively rare cause of acute pancreatitis with an incidence of 0.1-2%. Ocrelizumab is a monoclonal antibody that causes peripheral B lymphocyte suppression by targeting CD20 receptors on B lymphocytes. In this case report, we aimed to present a case of acute pancreatitis after ocrelizumab use. It is thought that suppression of B lymphocytes by ocrelizumab may induce proinflammatory cytokine release and may also cause pancreatitis by disrupting T lymphocyte regulation. Therefore, ocrelizumab should be considered in the etiology of pancreatitis in patients receiving ocrelizumab treatment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
